가상 임상시험 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 연구 디자인, 적응증, 단계, 지역별, 경쟁(2021-2031년)

The Global Virtual Clinical Trials Market is projected to expand significantly, growing from USD 8.79 Billion in 2025 to USD 16.46 Billion by 2031, demonstrating an 11.02% CAGR. This market is characterized by its reliance on decentralized research solutions, employing technologies such as telemedicine, remote patient monitoring, and digital data collection tools to conduct clinical studies with minimal physical site dependency. Key drivers include the crucial need for enhanced patient retention through increased convenience and the strategic goal of accessing broader, more diverse participant pools. For instance, in 2025, decentralized trial models showed a higher Asian participant representation of 20.9% compared to 14.2% in traditional studies, highlighting their effectiveness in overcoming geographical barriers and fostering representative clinical evidence.

Despite this growth, a significant obstacle to widespread market expansion is the inherent complexity of maintaining data integrity and ensuring regulatory compliance across varied, uncontrolled remote environments. Integrating diverse personal devices and digital platforms introduces both cybersecurity vulnerabilities and standardization challenges, creating substantial hurdles for sponsors aiming to meet stringent validation standards from global health authorities. As data proliferates outside traditional clinical settings, ensuring consistent quality assurance without overstraining site staff remains a persistent operational challenge.

Market Driver

The widespread adoption of telehealth and remote patient monitoring solutions is a primary accelerator for the Global Virtual Clinical Trials Market, as sponsors increasingly integrate digital tools to modernize study execution. This evolution is marked by a shift from isolated pilot projects to enterprise-wide deployment of platforms facilitating remote data capture and patient engagement. Medable's January 2025 press release, highlighting 80% revenue growth in 2024 from portfolio-level electronic Clinical Outcomes Assessment (eCOA) adoption, confirms a definitive industry movement towards scalable decentralized technologies. Furthermore, the operational success of these technologies is evidenced by wearable device studies, which, according to an October 2024 article by the Association of Clinical Research Professionals, demonstrated high patient adherence rates of 70% to 80%, affirming the viability of remote methods for consistent data generation.

Concurrently, an intensified focus on enhancing diversity and inclusion in clinical studies is actively propelling the adoption of virtual trial methods, enabling access to previously underrepresented demographics. Traditional site-based models often struggle with recruiting diverse populations due to geographical limitations, whereas decentralized approaches facilitate participation from a wider array of community settings. Findings from the Tufts Center for the Study of Drug Development in January 2025 indicated that enrollment of American Indian or Alaska Native participants in decentralized clinical trials reached 1.9%, nearly quadrupling the 0.5% rate typically seen in traditional studies. This data underscores virtual trials' capacity to bridge health equity gaps and align drug development with the diverse demographic realities of patient populations.

Market Challenge

Ensuring data integrity and regulatory compliance across uncontrolled remote environments presents a formidable challenge, significantly impeding the growth of the Global Virtual Clinical Trials Market. The reliance on a multitude of personal devices and diverse digital platforms introduces considerable variability in data quality, thereby complicating the validation processes mandated by health authorities. This absence of standardization compels sponsors to implement costly, redundant verification layers, which diminishes the efficiency gains typically associated with decentralized models and often causes companies to defer large-scale adoption to mitigate regulatory risks.

Moreover, the expanded digital footprint inherently magnifies cybersecurity threats, fostering significant hesitation regarding the security of sensitive patient information. The potential for data breaches in non-secure remote settings erodes trust and necessitates the implementation of resource-intensive security protocols that further burden site operations. A 2024 report by the Pistoia Alliance revealed that 41% of life science professionals identified data privacy and security concerns as a principal barrier to adopting new digital research technologies, illustrating how security vulnerabilities directly contribute to the industry's cautious approach and effectively slow market expansion as sponsors prioritize data safety over broader decentralized methodology deployment.

Market Trends

The integration of AI and machine learning for trial optimization is fundamentally reshaping the market by effectively managing the operational complexities involved in processing vast datasets from remote sensors and decentralized sources. As virtual trials progress beyond initial pilot phases, sponsors are making substantial investments in algorithmic capabilities to simulate study arms, accurately predict patient adherence, and automate real-time safety signal detection. This technological evolution transitions the industry from merely reactive monitoring to proactive, predictive study management, ensuring that the high volume of incoming digital data yields actionable clinical insights. This commitment to advanced technological infrastructure is evident in significant capital allocations, such as Thermo Fisher Scientific's clinical research business PPD investing $1.3 billion in research and development in 2023 for new technologies, including advanced disease simulation and AI integration.

Concurrently, the establishment of direct-to-patient drug supply and logistics is developing a robust physical infrastructure that complements the digital advancements in decentralized studies. This trend reflects the "Amazon-ification" of clinical supply chains, where the precise, often cold-chain, delivery of investigational medicinal products (IMPs) directly to patients' homes is transitioning from an exception to a standard operational requirement. To facilitate this model, contract development and manufacturing organizations are expanding their capacities to manage complex, temperature-sensitive, and drug-device combination therapies necessary for home administration. PCI Pharma Services, for instance, committed over $365 million in September 2024 to expand its EU and US facilities, specifically to support the clinical and commercial-scale assembly and packaging of drug-device combination products, directly addressing the increasing demand for patient-centric delivery mechanisms.

Key Market Players

• Medable, Inc.
• ICON, plc
• Parexel International Corporation
• Medidata Solutions Inc
• Oracle Corp
• Signant Health Holding Corp.
• Leo Laboratories Ltd
• IQVIA Inc
• PRA Health Sciences Inc
• Clinical Ink Inc

Report Scope

In this report, the Global Virtual Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Virtual Clinical Trials Market, By Study Design

• Interventional
• Observational
• Expanded Access

Virtual Clinical Trials Market, By Indication

• Oncology
• Cardiovascular Disease
• Others

Virtual Clinical Trials Market, By Phase

• Phase 1
• Phase 2
• Phase 3
• Phase 4

Virtual Clinical Trials Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Virtual Clinical Trials Market.

Available Customizations:

Global Virtual Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Virtual Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Study Design (Interventional, Observational, Expanded Access)
  • 5.2.2. By Indication (Oncology, Cardiovascular Disease, Others)
  • 5.2.3. By Phase (Phase 1, Phase 2, Phase 3, Phase 4)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Virtual Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Study Design
  • 6.2.2. By Indication
  • 6.2.3. By Phase
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Virtual Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Study Design
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Phase
  • 6.3.2. Canada Virtual Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Study Design
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Phase
  • 6.3.3. Mexico Virtual Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Study Design
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Phase

7. Europe Virtual Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Study Design
  • 7.2.2. By Indication
  • 7.2.3. By Phase
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Virtual Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Study Design
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Phase
  • 7.3.2. France Virtual Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Study Design
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Phase
  • 7.3.3. United Kingdom Virtual Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Study Design
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Phase
  • 7.3.4. Italy Virtual Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Study Design
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Phase
  • 7.3.5. Spain Virtual Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Study Design
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Phase

8. Asia Pacific Virtual Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Study Design
  • 8.2.2. By Indication
  • 8.2.3. By Phase
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Virtual Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Study Design
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Phase
  • 8.3.2. India Virtual Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Study Design
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Phase
  • 8.3.3. Japan Virtual Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Study Design
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Phase
  • 8.3.4. South Korea Virtual Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Study Design
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Phase
  • 8.3.5. Australia Virtual Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Study Design
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Phase

9. Middle East & Africa Virtual Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Study Design
  • 9.2.2. By Indication
  • 9.2.3. By Phase
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Virtual Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Study Design
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Phase
  • 9.3.2. UAE Virtual Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Study Design
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Phase
  • 9.3.3. South Africa Virtual Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Study Design
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Phase

10. South America Virtual Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Study Design
  • 10.2.2. By Indication
  • 10.2.3. By Phase
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Virtual Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Study Design
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Phase
  • 10.3.2. Colombia Virtual Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Study Design
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Phase
  • 10.3.3. Argentina Virtual Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Study Design
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Phase

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Virtual Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Medable, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ICON, plc
• 15.3. Parexel International Corporation
• 15.4. Medidata Solutions Inc
• 15.5. Oracle Corp
• 15.6. Signant Health Holding Corp.
• 15.7. Leo Laboratories Ltd
• 15.8. IQVIA Inc
• 15.9. PRA Health Sciences Inc
• 15.10. Clinical Ink Inc

16. Strategic Recommendations

17. About Us & Disclaimer